Indonesia plans to conduct clinical trials of TB vaccines from GSK, CanSino, and BioNTech to address rising cases and deaths.

Indonesia plans to begin clinical trials of TB vaccines from GlaxoSmithKline, CanSino Biologics, and BioNTech this year, as the country's TB cases rose from 820,000 in 2020 to an estimated 1 million in 2023. TB deaths reached 134,000 in 2022, the second highest in the world, leading to economic concerns. The country aims to lower TB mortality rate by 80% to six deaths per 100,000 lives by 2030.

June 10, 2024
3 Articles